Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Key facts

Sponsor

M.D. Anderson Cancer Center

Principal Investigator

Samer Srour, MD

M.D. Anderson Cancer Center

Intervention

Cyclophosphamide(drug)

Enrollment

11 enrolled

Eligibility

18-65 years · All sexes

Timeline

2017 – 2023

Study locations (1)

• M D Anderson Cancer Center, Houston, Texas, United States

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Acute myeloid leukemia with t(9;22)(q34.1;q11.2)

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT05031897
  Two Step Haplo With Radiation Conditioning
  Thomas Jefferson University
• ACTIVE NOT RECRUITINGPHASE2NCT04188405
  Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia
  M.D. Anderson Cancer Center
• ACTIVE NOT RECRUITINGPHASE1NCT02530034
  Hu8F4 in Treating Patients With Advanced Hematologic Malignancies
  M.D. Anderson Cancer Center
• RECRUITINGPHASE1NCT03630991
  Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
  M.D. Anderson Cancer Center
• ACTIVE NOT RECRUITINGPHASE2NCT03147612
  Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia
  M.D. Anderson Cancer Center
• ACTIVE NOT RECRUITINGPHASE2NCT02861417
  Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
  M.D. Anderson Cancer Center

See all trials for Acute myeloid leukemia with t(9;22)(q34.1;q11.2) →